Disease Information

General Information of the Disease (ID: DIS00223)

• Name: Alveolar soft part sarcoma
• ICD: ICD-11: 2F00

Type(s) of Resistant Mechanism of This Disease

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Doxorubicin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Resistant Disease: Alveolar soft part sarcoma [ICD-11: 2F00.Y]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Doxorubicin
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: MCF-7 cells; Breast; Homo sapiens (Human); CVCL_0031
• In Vitro Model: KHOS cells; Bone; Homo sapiens (Human); CVCL_2546
• In Vitro Model: KHOSR2 cells; Bone; Homo sapiens (Human); CVCL_T432
• In Vitro Model: ES-X cells; N.A.; .; N.A.
• In Vitro Model: VAESBJ cells; Bone; Homo sapiens (Human); CVCL_1785
• In Vitro Model: ASPS-KY cells; Lung; Homo sapiens (Human); CVCL_S737
• Experiment for Molecule Alteration: Western blotting assay
• Experiment for Drug Resistance: XTT assay
• Mechanism Description: In comparison to Dox-sensitive cells (MCF-7 and KHOS), P-gp mRNA expression was upregulated in all Dox-resistant cells (VAESBJ, ES-X, ASPS-KY and KHOSR2 cells).

References

• Ref 1: Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance .Oncotarget. 2016 Oct 25;7(43):70832-70844. doi: 10.18632/oncotarget.12225. 10.18632/oncotarget.12225